Inhibitory activity of Chinese medicine coptischinensisfranch against Staphylococcus aureus in vitro

doi:10.3969/j.issn.1673-8640.2017.07.005

Abstract

Abstract:

Objective To observe the inhibitory activity of Chinese medicine coptischinensisfranch against Staphylococcus aureus in vitro. Methods A total of 71 Staphylococcus aureus isolates were collected from Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine from January to April 2016. Broth micro-dilution method was used with Staphylococcus aureus ATCC 25913 as quality control isolate to observe the inhibitory activity of coptischinensisfranch. Results A total of 71 Staphylococcus aureus isolates were collected,and there were 21 isolates of methicillin-resistant Staphylococcus aureus （MRSA）. The minimal inhibitory concentration （MIC） of coptischinensisfranch against 71 isolates of Staphylococcus aureus was from 3.91 mg/mL to 31.25 mg/mL,and there was no statistical significance between MRSA and methicillin-sensitive Staphylococcus aureus （MSSA）（P>0.05）. Among the 71 isolates,52 isolates （73.24%） were isolated from pus/secretion specimens,while 19 isolates （26.76%）were isolated from the other specimens,and there was no statistical significance for the inhibitory activity of coptischinensisfranch against Staphylococcus aureus in vitro among different specimens（P>0.05）. Among the 71 isolates,40 isolates （56.34%）were isolated from surgical inpatients,25 isolates（35.21%）were isolated from the other ward inpatients,6 isolates （8.45%）were isolated from outpatients,and there was no statistical significance for the inhibitory activity of coptischinensisfranch against Staphylococcus aureus in vitro among different wards （P>0.05）. Conclusions Coptischinensisfranch has a good inhibitory activity against the clinical isolates of Staphylococcus aureus,and it can be used for the treatment of Staphylococcus aureus infection,especially for MRSA infection.

Key words: Coptischinensisfranch, Staphylococcus aureus, Inhibition, Minimal inhibitory concentration

CLC Number:

R446.5

YAO Dongting, HU Jun, ZHANG Xueqing, HU Xiaobo. Inhibitory activity of Chinese medicine coptischinensisfranch against Staphylococcus aureus in vitro[J]. Laboratory Medicine, 2017, 32(7): 577-581.

Figures/Tables 4

References 21

[1]	ERIKSEN N H,ESPERSEN F,ROSDAHL V T,et al.Carriage of Staphylococcus aureus among 104 healthy persons during a 19-month period[J]. Epidemiol Infect,1995,115(1): 51-60.
[2]	HUSEBY M J,KRUSE A C,DIGRE J,et al.Beta toxin catalyzes formation of nucleoprotein matrix in staphylococcal biofilms[J]. Proc Natl Acad Sci U S A,2010,107(32): 14407-14412.
[3]	KLUYTMANS J,VAN BELKUM A,VERBRUGH H.Nasal carriage of Staphylococcus aureus: epidemiology,underlying mechanisms,and associated risks[J]. Clin Microbiol Rev,1997,10(3): 505-520.
[4]	ELLIS M W,SCHLETT C D,MILLAR E V,et al.Prevalence of nasal colonization and strain concordance in patients with community-associated staphylococcus aureus skin and soft-tissue infections[J]. Infect Control Hosp Epidemiol,2014,35(10): 1251-1256.
[5]	WEINSTEIN H J.Control of nasalstaphylococcal-carrier states[J]. N Engl J Med,1959,260(26): 1308-1310.
[6]	VON EIFF C,BECKER K,MACHKA K,et al.Nasal carriage as a source of Staphylococcus aureus bacteremia. Study group[J]. N Engl J Med,2001,344(1): 11-16.
[7]	WERTHEIM H F,VOS M C,OTT A,et al.Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers[J]. Lancet,2004,364(9435): 703-705.
[8]	LISTER J L,HORSWILL A R.Staphylococcus aureus biofilms: recent developments in biofilm dispersal[J]. Front Cell Infect Microbiol,2014,4:178.
[9]	张显忠,郭爱军,李艳玲,等. 中草药提取物的体外抑菌活性研究[J]. 中华医院感染学杂志,2006,16(5):563-565.
[10]	王庆东,李丽娟,潘丽歆. 五味子等5种中药对耐甲氧西林金黄色葡萄球菌抑制作用的观察[J]. 中国伤残医学,2014,22(16):137-138.
[11]	彭苑霞,刘晓强,温羚玲,等. 大黄等5味中药及单体成分对临床多重耐药菌的抑制作用[J].中国实验方剂学杂志,2014,20(22):103-107.
[12]	李伟奇,刘湘新,李俊超,等. 10种中药提取物对耐药金黄色葡萄球菌抑菌作用的研究[J]. 动物医学进展,2010,31(9):41-46.
[13]	CECH N B,JUNIO H A,ACKERMANN L W,et al.Quorum quenching and antimicrobial activity of goldenseal(Hydrastis canadensis) against methicillin-resistant Staphylococcus aureus (MRSA)[J]. Planta Med,2012,78(14): 1556-1561.
[14]	JANOVSKA D,KUBIKOVA K,KOKOSKA L.Screening for antimicrobial activity of some medicinal plants species of traditional Chinese medicine[J]. Czech J Food Sci,2003,21(3): 107-110.
[15]	YANG Z C,WANG B C,YANG X S,et al.The synergistic activity of antibiotics combined with eight traditional Chinese medicines against two different strains of Staphylococcus aureus[J]. Colloids Surf B Biointerfaces,2005,41(2-3): 79-81.
[16]	谢梅,徐春红,胡正波,等. 管碟法比较盐酸小檗碱和黄连药材对金色葡萄球菌的抑菌效力[J]. 中国药业,2012,21(19):9-11.
[17]	秦卫红,田兰,田华咏,等. 土家药山黄连抑菌实验研究[J]. 中国民族医药杂志,2013,19(9):47-48.
[18]	赵凌旭,王蕾. 中药黄檗对金黄色葡萄球菌体外抑菌效果的初步研究[J]. 检验医学,2015,30(9):886-889.
[19]	潘杰,苗霞,刘启波,等. 12种中药配方颗粒体外逆转临床常见细菌耐药性分析[J]. 检验医学,2016,31(6):503-508.
[20]	梁晓谊,朱海英,刘笑梅,等. 两组中药方剂对糖尿病足产ESBLs大肠埃希菌和MRSA体外药物敏感性试验结果分析[J]. 检验医学,2015,30(3):261-264.
[21]	李蔼文,谭俊青,王康椿,等. 5种中药颗粒剂与水煎剂对5种耐药菌株的体外抑菌作用比较[J]. 检验医学,2015,30(6):567-570.

抗菌药物	敏感	中介	耐药
氨苄西林	83.10	12.68	4.22
头孢唑啉	78.87	16.90	4.23
替考拉宁	100.00	0.00	0.00
青霉素	9.86	0.00	90.14
苯唑西林	70.42	0.00	29.58
庆大霉素	83.10	0.00	16.90
环丙沙星	71.83	5.63	22.54
左氧氟沙星	78.87	4.23	16.90
莫西沙星	84.51	2.81	12.68
红霉素	43.66	1.41	54.93
克林霉素	71.83	0.00	28.17
奎奴普汀	100.00	0.00	0.00
利奈唑胺	100.00	0.00	0.00
万古霉素	100.00	0.00	0.00
四环素	71.83	0.00	28.17
替加环素	100.00	0.00	0.00
呋喃妥因	98.59	1.41	0.00
利福平	94.37	0.00	5.63
复方磺胺甲噁唑	97.18	0.00	2.82

抗菌药物	敏感	中介	耐药
氨苄西林	83.10	12.68	4.22
头孢唑啉	78.87	16.90	4.23
替考拉宁	100.00	0.00	0.00
青霉素	9.86	0.00	90.14
苯唑西林	70.42	0.00	29.58
庆大霉素	83.10	0.00	16.90
环丙沙星	71.83	5.63	22.54
左氧氟沙星	78.87	4.23	16.90
莫西沙星	84.51	2.81	12.68
红霉素	43.66	1.41	54.93
克林霉素	71.83	0.00	28.17
奎奴普汀	100.00	0.00	0.00
利奈唑胺	100.00	0.00	0.00
万古霉素	100.00	0.00	0.00
四环素	71.83	0.00	28.17
替加环素	100.00	0.00	0.00
呋喃妥因	98.59	1.41	0.00
利福平	94.37	0.00	5.63
复方磺胺甲噁唑	97.18	0.00	2.82

黄连稀释比例	脓/分泌物	痰和咽拭	腹透液	中段尿	血培养	合计
1∶32	4	0	0	0	0	4
1∶64	6	4	0	1	1	12
1∶128	19	0	5	1	1	26
1∶256	23	3	1	2	0	29
合计	52	7	6	4	2	71

黄连稀释比例	脓/分泌物	痰和咽拭	腹透液	中段尿	血培养	合计
1∶32	4	0	0	0	0	4
1∶64	6	4	0	1	1	12
1∶128	19	0	5	1	1	26
1∶256	23	3	1	2	0	29
合计	52	7	6	4	2	71

黄连稀释比例	外科	门诊	其他科室	合计
1∶32	4	0	0	4
1∶64	8	0	4	12
1∶128	13	2	11	26
1∶256	15	4	10	29
合计	40	6	25	71